Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Purple Biotech (PPBT)
NASDAQ:PPBT
Holding PPBT?
Track your performance easily
PPBT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.30 - $7.83
Previous Close$2.81
Volume44.65K
Average Volume (3M)112.45K
Market Cap
$5.34M
Enterprise Value-$9.63M
Total Cash (Recent Filing)$15.41M
Total Debt (Recent Filing)$351.00K
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Feb 05, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.33
Shares Outstanding1,413,797
10 Day Avg. Volume80,752
30 Day Avg. Volume112,450
Standard Deviation0.28
R-Squared0.04
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.11
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.17
Forecast
1Y Price Target
$33.00Price Target Upside1179.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Purple Biotech News
PremiumCompany Announcements
Purple Biotech Unveils Promising Biomarker for Cancer Therapy
PremiumCompany Announcements
Purple Biotech Advances with CAPTN-3 Cancer Platform
PremiumCompany Announcements
Purple Biotech Unveils CAPTN-3 Cancer Therapy
PremiumCompany Announcements
Purple Biotech Anticipates Key Clinical MilestonesBulls Say, Bears Say
Bulls Say
Biomarker AnalysisVarious biomarker analysis on the Phase 2 CM24 trial demonstrates improved overall survival.
Safety And ActivityNT219 + cetuximab demonstrated safety and early activity in patients with relapsed/metastatic squamous cell carcinoma of the head & neck, showing dose-proportional pharmacokinetic values.
Therapy EfficacyThe CM24 experimental arm had consistently greater efficacy for every evaluated endpoint.
Bears Say
Adverse EventsA higher number of Grade 3+ treatment-emergent adverse events were reported, including increased rates of diarrhea and fatigue, compared to the control group.
Clinical Trial ImbalanceThe gem/nab-paclitaxel cohort experienced an imbalance due to informative censoring, making it unsuitable for analysis.
Resource RequirementsAdvancing the NT219 program may require additional resources, despite being ready for Phase 2.
---
Ownership Overview
―
Insiders
― Other Institutional Investors
100.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PPBT FAQ
What was Purple Biotech’s price range in the past 12 months?
Purple Biotech lowest stock price was $0.30 and its highest was $7.83 in the past 12 months.
What is Purple Biotech’s market cap?
Currently, no data Available
When is Purple Biotech’s upcoming earnings report date?
Purple Biotech’s upcoming earnings report date is Feb 05, 2025 which is in 85 days.
How were Purple Biotech’s earnings last quarter?
Currently, no data Available
Is Purple Biotech overvalued?
According to Wall Street analysts Purple Biotech’s price is currently Undervalued.
Does Purple Biotech pay dividends?
Purple Biotech does not currently pay dividends.
What is Purple Biotech’s EPS estimate?
Purple Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Purple Biotech have?
Purple Biotech has 1,822,626 shares outstanding.
What happened to Purple Biotech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Purple Biotech?
Among the largest hedge funds holding Purple Biotech’s share is Fisher Asset Management LLC. It holds Purple Biotech’s shares valued at N/A.
---
Purple Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.00 (1179.07% Upside)
$33.00 (1179.07% Upside)
Hedge Fund Trend
Decreased
By 32.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 10.4%
Last 30 Days ▲ 10.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
160.18%
12-Months-Change
Fundamentals
Return on Equity
-44.58%
Trailing 12-Months
Asset Growth
-24.86%
Trailing 12-Months
Company Description
Purple Biotech
Kitov Pharma Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack in June 2010 and is headquartered in Tel Aviv, Israel.
---
PPBT Stock 12 Month Forecast
Average Price Target
$33.00
▲(1179.07% Upside)
Technical Analysis
Best Analysts Covering PPBT
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+217.86%
assigned a buy rating 2 months ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +217.86% per trade.
---